219 related articles for article (PubMed ID: 31663454)
21. Effect of a Fluocinolone Acetonide Insert on Recurrence Rates in Noninfectious Intermediate, Posterior, or Panuveitis: Three-Year Results.
Jaffe GJ; Pavesio CE;
Ophthalmology; 2020 Oct; 127(10):1395-1404. PubMed ID: 32624244
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of fluocinolone acetonide sustained release implant (Retisert) dissociation during implant removal and exchange surgery.
Nicholson BP; Singh RP; Sears JE; Lowder CY; Kaiser PK
Am J Ophthalmol; 2012 Dec; 154(6):969-973.e1. PubMed ID: 22981365
[TBL] [Abstract][Full Text] [Related]
23. Yutiq - another fluocinolone intravitreal implant for uveitis.
Med Lett Drugs Ther; 2021 Jul; 63(1629):e5-e6. PubMed ID: 34544110
[No Abstract] [Full Text] [Related]
24. Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion.
Nguyen QD; Callanan D; Dugel P; Godfrey DG; Goldstein DA; Wilensky JT
Retina; 2006 Oct; Suppl():1-16. PubMed ID: 17050954
[TBL] [Abstract][Full Text] [Related]
25. Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis.
; Kempen JH; Altaweel MM; Holbrook JT; Sugar EA; Thorne JE; Jabs DA
JAMA; 2017 May; 317(19):1993-2005. PubMed ID: 28477440
[TBL] [Abstract][Full Text] [Related]
26. Combined Ahmed Glaucoma Valve Placement, Intravitreal Fluocinolone Acetonide Implantation and Cataract Extraction for Chronic Uveitis.
Chang IT; Gupta D; Slabaugh MA; Vemulakonda GA; Chen PP
J Glaucoma; 2016 Oct; 25(10):842-846. PubMed ID: 27300641
[TBL] [Abstract][Full Text] [Related]
27. Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant.
Ciulla TA; Harris A; McIntyre N; Jonescu-Cuypers C
Expert Opin Pharmacother; 2014 May; 15(7):953-9. PubMed ID: 24661081
[TBL] [Abstract][Full Text] [Related]
28. Longitudinal Vision-Related Quality of Life for Patients with Noninfectious Uveitis Treated with Fluocinolone Acetonide Implant or Systemic Corticosteroid Therapy.
Sugar EA; Venugopal V; Thorne JE; Frick KD; Holland GN; Wang RC; Almanzor R; Jabs DA; Holbrook JT;
Ophthalmology; 2017 Nov; 124(11):1662-1669. PubMed ID: 28624167
[TBL] [Abstract][Full Text] [Related]
29. Fluocinolone acetonide implantable device for diabetic retinopathy.
Schwartz SG; Flynn HW
Curr Pharm Biotechnol; 2011 Mar; 12(3):347-51. PubMed ID: 20939799
[TBL] [Abstract][Full Text] [Related]
30. Time to disease recurrence in noninfectious uveitis following long-acting injectable fluocinolone acetonide implant.
Cai CX; Skalak C; Keenan RT; Grewal DS; Jaffe GJ
Graefes Arch Clin Exp Ophthalmol; 2020 May; 258(5):1023-1030. PubMed ID: 32114654
[TBL] [Abstract][Full Text] [Related]
31. Fluocinolone acetonide for the treatment of uveitis: weighing the balance between local and systemic immunosuppression.
Yeh S; Nussenblatt RB
Arch Ophthalmol; 2008 Sep; 126(9):1287-9. PubMed ID: 18779492
[No Abstract] [Full Text] [Related]
32. Fluocinolone acetonide 0.19-mg implant for the treatment of noninfectious uveitis with involvement of the posterior segment: a real-world study.
Buhl L; Thurau S; Kern C
Graefes Arch Clin Exp Ophthalmol; 2023 Apr; 261(4):1101-1108. PubMed ID: 36399176
[TBL] [Abstract][Full Text] [Related]
33. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis.
Arcinue CA; Cerón OM; Foster CS
J Ocul Pharmacol Ther; 2013 Jun; 29(5):501-7. PubMed ID: 23297752
[TBL] [Abstract][Full Text] [Related]
34. Retisert (Bausch & Lomb/Control Delivery Systems).
Lim LL; Smith JR; Rosenbaum JT
Curr Opin Investig Drugs; 2005 Nov; 6(11):1159-67. PubMed ID: 16312138
[TBL] [Abstract][Full Text] [Related]
35. Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study.
Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group
Ophthalmology; 2015 Oct; 122(10):1976-86. PubMed ID: 26298718
[TBL] [Abstract][Full Text] [Related]
36. Drug delivery options for the treatment of ocular inflammation.
Lobo AM; Sobrin L; Papaliodis GN
Semin Ophthalmol; 2010; 25(5-6):283-8. PubMed ID: 21091013
[TBL] [Abstract][Full Text] [Related]
37. The therapeutic potential of intraocular depot steroid systems: developments aimed at prolonging duration of efficacy.
Nentwich MM; Ulbig MW
Dtsch Arztebl Int; 2012 Sep; 109(37):584-90. PubMed ID: 23093988
[TBL] [Abstract][Full Text] [Related]
38. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants.
Campochiaro PA; Nguyen QD; Hafiz G; Bloom S; Brown DM; Busquets M; Ciulla T; Feiner L; Sabates N; Billman K; Kapik B; Green K; Kane FE;
Ophthalmology; 2013 Mar; 120(3):583-587. PubMed ID: 23218184
[TBL] [Abstract][Full Text] [Related]
39. Outcome of fluocinolone acetonide implant (Retisert) reimplantation for chronic noninfectious posterior uveitis.
Taban M; Lowder CY; Kaiser PK
Retina; 2008 Oct; 28(9):1280-8. PubMed ID: 18628725
[No Abstract] [Full Text] [Related]
40. Spontaneous Dissociation of Fluocinolone Acetonide Sustained Release Implant (Retisert) with Dislocation into the Anterior Chamber.
Chang PY; Kresch Z; Samson CM; Gentile RC
Ocul Immunol Inflamm; 2015; 23(6):454-7. PubMed ID: 24724735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
